Top stories in health and medicine, November 7, 2014
From MedPage Today:
Old COX-2 Inhibitors Tied to Stroke Mortality. New use of nonsteroidal anti-inflammatory drugs of the first generation that selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, such as diclofenac and etodolac, was associated with increased 30-day mortality following ischemic stroke in a Danish database analysis.
Edoxaban Reversal Agent in the Works. A small molecule agent appeared promising as a reversal agent for the novel anticoagulant edoxaban (Savaysa), based on early-stage results.
Speed Is Ebola Vaccine Trial Goal. Results from trials of Ebola vaccines and therapeutics will be analyzed constantly to find the earliest possible signal of efficacy, a “novel” approach to randomized trials, an FDA expert said.
California Nixes Random Drug Testing for Docs. California voters overwhelmingly turned down a ballot proposition Tuesday that would have raised the medical malpractice cap and required drug testing for some healthcare workers in the state.
Your patients are rating you online: How to respond. Manage your online reputation: A social media guide. Find out how.
Source: Kevin, M.D. - Medical Weblog - Category: Journals (General) Authors: MedPage Today Tags: News Heart Infectious disease Neurology Source Type: blogs
More News: Blogging | Brain | Cardiology | Databases & Libraries | Diclofenac | Ebola | Ebola Vaccine | Etodolac | Family Physicians | Health | Heart | Infectious Diseases | Ischemic Stroke | Malpractice | Neurology | Stroke | Vaccines | Voltaren